Scott L. Spear

Staged Breast Reconstruction with Saline-filled Implants in the Irradiated Breast: Recent Trends and Therapeutic Implications

A retrospective review was performed of one surgeon’s experience with 40 consecutive patients who had undergone two-stage saline-filled implant breast reconstruction and radiation during the period from 1990 through 1997. A randomly selected group of 40 other two-stage saline-filled implant breast reconstructions from the same surgeon and time period served as controls. This review was undertaken because of the absence of specific information on the outcome of staged saline implant reconstructions in the radiated breast. Previously published reports on silicone gel implants and radiation have been contradictory. At the same time, the criteria for the use of radiation in the treatment of breast cancer have been expanded and the numbers of reconstruction patients who have been radiated are increasing dramatically. For example, in a 1985 report on immediate breast reconstruction, only 1 of 185 patients over a 6-year period underwent adjuvant radiation therapy, whereas in this review, there were 40 radiated breasts with saline-filled implants, 19 of which received adjuvant radiation therapy during their expansion. The study parameters included patient age, breast cup size, implant size, length of follow-up, number of procedures, coincident flap operations, Baker classification, complications, opposite breast procedures, pathologic stage, indications for and details about the radiation, and outcomes. The use of radiation in this review of reconstructed breasts can logically be divided into four groups: previous lumpectomy and radiation (n = 7), mastectomy and radiation before reconstruction (n = 9), mastectomy and adjuvant radiation during reconstruction/expansion (n = 19), and radiation after reconstruction (n = 5). The largest and most rapidly growing group of patients is of those receiving postmastectomy adjuvant radiation therapy. A total of 47.5 percent (19 of 40) of radiated breasts with saline implants ultimately needed the addition of, or replacement by, a flap. Ten percent of a control group with nonradiated saline implant reconstructions also had flaps, none as replacements. Fifty percent or more of both the radiated and control groups had contralateral surgery. Complications were far more common in the radiated group; for example, there were 32.5 percent capsular contractures compared with none in the control group. The control nonradiated implant-only group and the flap plus implant radiated group did well cosmetically. The radiated implant-only group was judged the worst. The increasing use of radiation after mastectomy has important implications for breast reconstruction. The possibility for radiation should be thoroughly investigated and anticipated preoperatively before immediate breast reconstruction. Patients with invasive disease, particularly with large tumors or palpable axillary lymph nodes, are especially likely to be encouraged to undergo postmastectomy radiation therapy. The indications for adjuvant radiation therapy have included four or more positive axillary lymph nodes, tumors 4 cm (or more) in diameter, and tumors at or near the margin of resection. More recently, some centers are recommending adjuvant radiation therapy for patients with as few as one positive lymph node or even in situ carcinoma close to the resection margin. The use of latissimus dorsi flaps after radiation has proven to be an excellent solution to postradiation tissue contracture, which can occur during breast expander reconstruction. The use of the latissimus flap electively with skin-sparing mastectomy preradiation is probably unwise, unless postmastectomy radiation is unlikely. Skin-sparing mastectomy with a latissimus flap thus should be preserved for patients unlikely to undergo adjuvant radiation therapy. Purely autologous reconstruction such as a TRAM flap is another option for these patients, either before or after radiation therapy. (Plast. Reconstr. Surg. 105: 930, 2000.)

Classification of capsular contracture after prosthetic breast reconstruction.

The Baker classification of capsular contracture remains the most popular and practical method of assessing clinical firmness of the breast after augmentation mammaplasty. This classification system was never intended to describe prosthetic breast reconstruction. A modification of the Baker classification to include classes IA, IB, II, III, and IV has been developed to describe breast reconstruction more accurately. For this modified system, a soft but visible implant (class IB), an implant with mild firmness (class II), and an implant with moderate firmness (class III) could still be considered good or excellent outcomes. Only a class IV classification with an excessively firm and symptomatic breast resulting in a poor aesthetic result would necessarily be considered a poor outcome.

Fat Injection to Correct Contour Deformities in the Reconstructed Breast

Background: A ten-year, single-surgeon study of 37 patients from 1993 to 2003 who underwent fat injections to improve contour deformities in their reconstructed breasts was reviewed. Methods: Fat was harvested from elsewhere in the body using a low-pressure syringe lipoaspiration system, washed gently with saline, and injected into depressions along the margins of reconstructed breasts. Blinded physician observers judged preoperative and postoperative photographs of breasts injected with fat and categorized the degree of contour improvement as substantial, minimal to moderate, or none. Complications of fat injections were noted. A total of 43 breasts in 37 patients were injected with autologous fat during 47 discrete events; some patients had the procedure repeated and some were treated bilaterally. Of the 43 treated breasts, 25 (58 percent) were reconstructed with implants, 17 (40 percent) were reconstructed with a TRAM (transverse rectus abdominis muscle) flap, and one (2 percent) was reconstructed with a TRAM and an implant. Results: There were four complications (8.5 percent) in 47 treated breasts: one breast with cellulitis that resolved with antibiotics and three breasts with small, superficial lumps–two of which were biopsied and found to be liponecrotic cysts. Patient follow-up averaged 49 weeks, ranging from 3 weeks to 6 years. There was a substantial contour improvement in ten breasts (21 percent), minimal to moderate improvement in 30 breasts (64 percent), and no improvement in 7 breasts (15 percent). Conclusions: Although fat injection in and around the reconstructed breast has limitations, such as fat necrosis and need for repeated injections, our experience indicates that overall it is a very safe technique that can improve or correct significant contour deformities that otherwise would require more complicated, riskier procedures to improve.

Immediate breast reconstruction in two stages using textured, integrated-valve tissue expanders and breast implants : A retrospective review of 171 consecutive breast reconstructions from 1989 to 1996

&NA; A 7‐year experience with 171 consecutive immediate breast reconstructions by one surgeon using a textured integrated‐valve tissue expander was reviewed. All patients were reconstructed in multiple stages using a temporary biodimensional tissue expander followed months later by a long term implant. There was one (0.6 percent) spontaneous expander deflation that was replaced. Two (1.2 percent) expanders were removed for infection, and one was removed electively. Fourteen patients (8 percent) had flaps as well as expanders. Initially, expanders were replaced with silicone gel‐filled and round saline‐filled implants. Later, expanders were replaced mostly with anatomically designed textured saline‐filled implants. Of the 171 expanders, 139 were thus ultimately followed by such anatomic designs. Seven (4 percent) of the implants were replaced because of deflation over 7 years. Five patients were lost to follow‐up during the expansion phase of their reconstruction. Thirteen percent of these reconstructions received local radiation either before, during, or after expansion. There were a total of five (2.9 percent) significant capsular contractures, with four of them occurring in radiated patients. Ninety‐eight percent of a subgroup of 42 consecutively queried patients expressed satisfaction with their reconstruction, while only 2 percent of the queried patients were dissatisfied. (Plast. Reconstr. Surg. 101: 53, 1998.)

Inamed silicone breast implant core study results at 6 years.

Background: Silicone gel–filled breast implants were developed in 1962 but did not fall under the auspices of the U.S. Food and Drug Administration until 1976 and were not classified as class III devices until 1988. This set the stage for a series of Food and Drug Administration advisory panel meetings and a moratorium on the sale of these implants from 1992 until 2006, when sufficient clinical data were presented to demonstrate their safety. Methods: This study was conducted under the rigorous framework of a Food and Drug Administration–approved investigational device exemption to document the safety and effectiveness of Inamed silicone-filled breast implants through 10 years. Of 940 female subjects, approximately half were augmentation subjects, one-quarter were reconstruction subjects, and one-quarter were revision subjects. Follow-up visits were conducted at 0 to 4 weeks, 6 months, 1 year, and annually thereafter. Approximately one-third of subjects also underwent biennial magnetic resonance imaging evaluation to detect silent rupture. Primary statistical analyses used the Kaplan-Meier product limit method. Results: Data through 6 years are currently available from the 10-year study, with patient follow-up rates for that visit ranging from 78 to 92 percent per cohort. As expected, the most common local complication in all cohorts was capsular contracture, occurring in 15 to 20 percent of subjects. The by-implant rupture rate was 3.5 percent overall at 6 years. Satisfaction with implants was uniformly high throughout the study period, with 6-year rates of 95 percent for augmentation subjects and 94 percent for reconstruction subjects. Conclusion: Study results demonstrate the safety and effectiveness of Inamed silicone-filled breast implants through 6 years, including a low rupture rate and high satisfaction rate.

Prevention of venous thromboembolism in the plastic surgery patient.

The term venous thromboembolism refers to a spectrum of disease that includes deep venous thrombosis and pulmonary embolism. Both deep venous thrombosis and pulmonary embolism are often clinically silent and thus difficult to diagnose, which leads to a substantial delay in treatment that results in high rates of morbidity and mortality. The purposes of this article are to help physicians determine the proper venous thromboembolism prophylaxis and to simplify the complex problem of treating venous thromboembolism. The tools provided in this article will help expedite and clarify the decision-making process.

Nipple-sparing mastectomy for prophylactic and therapeutic indications.

Background: Nipple-sparing mastectomy remains controversial and its adoption has been slow because of oncologic and surgical concerns. Methods: A retrospective study evaluated all nipple-sparing mastectomies performed at a single institution for therapeutic or prophylactic indications for which records were available. Results: Between 1989 and 2010, 162 nipple-sparing mastectomies were performed in 101 women. Forty-nine (30 percent) were performed for therapeutic purposes on 48 patients. A subareolar biopsy specimen was taken in 39 of 49 breasts (80 percent); four (10 percent) revealed ductal carcinoma in situ, and the nipple or nipple-areola complex was later removed. Four of 49 breasts (8 percent) in the therapeutic group had ischemic complications involving the nipple-areola complex, one of which (2 percent) was excised. With a mean follow-up of 2 years 6 months (range, 5 months to 9 years 5 months), no patients developed cancer in the nipple-areola complex. The remaining 113 mastectomies (70 percent) were performed prophylactically on 80 patients. The subareolar tissue was biopsied in 80 breasts (71 percent). One biopsy revealed lobular carcinoma in situ; none had ductal carcinoma in situ or invasive cancer. Two nipple-areola complexes (1.8 percent) were ischemic and excised. With a mean follow-up of 3 years 7 months (range, 5 months to 20 years 6 months), no patients developed new primary cancers in the nipple-areola complex. Conclusions: Nipple-sparing mastectomy can be safe in properly selected patients. A subareolar biopsy can effectively identify nipple-areola complexes that may harbor cancerous cells. Ischemic complications resulting in nipple loss can be minimized, and long-term follow-up suggests that this technique deserves further investigation in properly selected patients. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

Breast reconstruction with implants and expanders

Breast reconstruction with expanders and implants provides an excellent option in the properly selected patient. Techniques for reconstruction have evolved significantly over the past 30 years with the development of more sophisticated devices and improvement in surgical procedures. Several options exist, each with its own advantages and disadvantages. Two-stage breast reconstruction using a textured device with an anatomic shape and integrated valve seems to provide the most consistent and reproducible results in most patients. Those patients with small, minimally ptotic breasts may be candidates for either single-stage implant reconstruction or reconstruction with an adjustable device. Advantages of expander and implant reconstruction over other techniques include relative ease of the procedure; no distant donor-site morbidity; use of tissue of similar color, texture, and sensation; reduced operative time; and more rapid postoperative recovery.

Improvements in cardiovascular risk profile with large-volume liposuction: a pilot study.

In this study, the authors investigated the physiologic effects of the altered body composition that results from surgical removal of large amounts of subcutaneous adipose tissue. Fourteen women with body mass indexes of greater than > 27 kg/m2 underwent measurements of fasting plasma insulin, triglycerides, cholesterol, body composition by dual-energy x-ray absorptiometry (DXA), resting energy expenditure, and blood pressure before and after undergoing large-volume ultrasound-assisted liposuction. There were no significant intraoperative complications. Body weight had decreased by 5.1 kg (p < 0.0001) by 6 weeks after liposuction, with an additional 1.3-kg weight loss (p < 0.05) observed between 6 weeks and 4 months after surgery, for a total weight loss of 6.5 kg (p < 0.00006). Body mass index decreased from (mean +/- SEM) 28.8 +/- 2.3 to 26.8 +/- 1.5 kg/m2 (p < 0.0001). This change in body weight was primarily the result of decreases in body fat mass: as assessed by DXA, lean body mass did not change (43.8 +/- 3.1 kg to 43.4 +/- 3.6 kg, p = 0.80), whereas DXA total body fat mass decreased from 35.7 +/- 6.3 to 30.1 +/- 6.5 kg (p < 0.0001). There were significant decreases in fasting plasma insulin levels (14.9 +/- 6.5 mIU/ml before liposuction versus 7.2 +/- 3.2 mIU/ml 4 months after liposuction, p < 0.007), and systolic blood pressure (132.1 +/- 7.2 versus 120.5 +/- 7.8 mmHg, p < 0.0002). Total cholesterol, high-density lipoprotein cholesterol, plasma triglycerides, and resting energy expenditure values were not significantly altered after liposuction. In conclusion, over a 4-month period, large-volume liposuction decreased weight, body fat mass, systolic blood pressure, and fasting insulin levels without detrimental effects on lean body mass, bone mass, resting energy expenditure, or lipid profiles. Should these improvements be maintained over time, liposuction may prove to be a valuable tool for reducing the comorbid conditions associated with obesity.

Effect of obesity on flap and donor-site complications in pedicled TRAM flap breast reconstruction.

Background: The detrimental effects of obesity on pedicled and free transverse rectus abdominis myocutaneous (TRAM) flap reconstructions, including flap loss, hematoma, and donor-site hernia, are well documented. This study examined the effect of obesity on complications in patients undergoing pedicled TRAM flap breast reconstruction. Methods: A retrospective review of 224 pedicled TRAM flaps in 200 patients over a 10-year period was carried out. Patients were divided into three groups: normal weight (body mass index < 25; 47 percent of patients), overweight (body mass index 25 to 29.9; 38 percent), and obese (body mass index ≥ 30; 15 percent). There were no statistically significant differences in age, smoking history, radiation/chemotherapy history, distribution of flap pedicle types, timing of reconstruction, percentage of delay procedures performed, or expanders implanted among the three subgroups. Donor-site, flap, and other miscellaneous complications were compared among subgroups, and logistic regression analysis was used to identify risk factors for flap and donor-site complications. Results: Compared with normal weight and overweight patients, obese patients had a statistically significantly higher incidence of multiple flap complications (36.7 percent versus 10.6 percent and 36.7 percent versus 10.5 percent, respectively; p = 0.0036) and partial flap necrosis (21.6 percent versus 5.8 percent and 21.6 percent versus 7.1 percent; p = 0.01 and p = 0.03, respectively). Lastly, obese patients had a significantly higher incidence of overall (one or more) donor-site complications when compared with normal weight patients (53.3 percent versus 31.9 percent; p = 0.0499). Conclusion: Obese patients, in contrast to normal weight and overweight patients, have a statistically significantly higher risk for developing overall (one or more) and multiple flap complications, overall donor-site complications, TRAM flap delayed wound healing, and minor flap necrosis.